Abstract
The article reporting on risperidone use in children with autism (Aug. 1 issue)1 left many questions unanswered. Over an eight-week period, the treatment group had documented weight gains of about 6 lb (2.7 kg). The article indicates that increased “fatigue, drowsiness, dizziness, and drooling” occurred at significant rates. One has to wonder whether the increased drowsiness and dizziness in the children was just one of many unaccounted-for variables that lessened their “irritability.”

This publication has 9 references indexed in Scilit: